Guide · Updated March 2026

GLP-1 Medicare Coverage in 2026: The $50/Month Program Explained

Medicare now covers GLP-1 medications for qualifying beneficiaries in 2026, after decades of explicit exclusion. The $50/month cost-sharing cap applies to Low Income Subsidy (Extra Help) beneficiaries under the redesigned Part D structure. Medicare Advantage plans can now include obesity pharmacotherapy as a supplemental benefit. Wegovy has the broadest Medicare coverage due to its FDA-approved cardiovascular indication from the SELECT trial.

For years, Medicare explicitly banned coverage for weight loss drugs. There was actually a law on the books, dating back to 2003, that prohibited Part D plans from covering obesity medications. If you were on Medicare and wanted Wegovy or Zepbound, you paid full list price. That was $1,349/month for Wegovy and $1,086/month for Zepbound as of early 2026.

That changed. The Inflation Reduction Act amendments and subsequent CMS guidance have opened the door to GLP-1 Medicare coverage in 2026, and a $50/month cost-sharing cap is now available to qualifying beneficiaries through specific plan structures. But the coverage is not automatic, not universal, and not as simple as the headlines make it sound.

Here is what the program actually covers, who qualifies, and where the gaps still exist.

How GLP-1 Medicare Coverage Actually Works in 2026

The legal barrier to Medicare covering obesity drugs was Section 1860D-2(e)(2) of the Social Security Act. It explicitly excluded drugs used “for anorexia, weight loss, or weight gain.” For GLP-1s prescribed purely for obesity, this was a hard block.

The workaround that has been in place since 2023 is coverage for cardiovascular indications. After the SELECT trial showed that semaglutide 2.4mg (Wegovy) reduced major cardiovascular events by 20% in people with established cardiovascular disease (NEJM, 2023), CMS allowed Part D plans to cover Wegovy when prescribed for cardiovascular risk reduction in patients with BMI 27+ and existing heart disease.

That was a partial fix. It helped some Medicare beneficiaries but excluded anyone whose primary diagnosis was obesity without documented cardiovascular disease.

The 2026 updates expanded this in two important ways:

First, CMS finalized guidance allowing Medicare Advantage plans to include obesity pharmacotherapy as a supplemental benefit. This means individual MA plans can elect to cover GLP-1s for obesity, and many have added this for 2026 plan years.

Second, the $50/month cost-sharing cap applies to covered drugs under the redesigned Part D structure that took effect in 2025. Under the Inflation Reduction Act’s Part D redesign, there is a $2,000 annual out-of-pocket cap, and monthly cost-sharing for covered drugs is capped at $50 per drug for low-income subsidy (LIS) beneficiaries. For non-LIS beneficiaries, cost-sharing varies by plan, but CMS has pushed plans to keep GLP-1 cost-sharing low where coverage exists.

The $50/month figure you see in headlines specifically applies to LIS/Extra Help beneficiaries. If you do not qualify for Extra Help, your copay depends on your specific plan’s formulary tier.

Who Actually Qualifies for the $50/Month Cap

Let me break this down clearly because there are several overlapping eligibility criteria.

Medicare Eligibility Itself

You need to be enrolled in Medicare Part D or a Medicare Advantage plan that includes prescription drug coverage. Original Medicare (Parts A and B only) does not cover outpatient prescription drugs.

Drug Coverage Eligibility

Your plan must actually cover the GLP-1 you are prescribed. As of March 2026, coverage varies significantly by plan. Wegovy has the broadest coverage because of its FDA-approved cardiovascular indication. Zepbound’s coverage for obesity specifically depends entirely on whether your Medicare Advantage plan elected to include it as a supplemental benefit.

If your plan does not include GLP-1s on its formulary, the $50 cap does not help you at all. You would pay full price or go through an exception process.

Clinical Eligibility

For the cardiovascular indication (which drives most Part D coverage), you generally need:

• BMI of 27 or higher
• Established cardiovascular disease (prior heart attack, stroke, or confirmed atherosclerosis)
• A physician willing to document the cardiovascular risk reduction indication

For obesity-only coverage through Medicare Advantage supplemental benefits, plans typically require:

• BMI of 30 or higher, or 27 with a weight-related comorbidity
• Prior authorization approval
• Documentation of previous weight loss attempts

The Extra Help / Low-Income Subsidy Requirement for $50 Cap

The flat $50/month cap is a feature of the Extra Help program, not standard Part D. You qualify for Extra Help if your income is below about 150% of the federal poverty level (roughly $21,870 for a single person in 2026) and your assets fall below CMS thresholds.

If you qualify for both Medicare and Medicaid (dual eligible), you automatically get Extra Help. If you are not sure whether you qualify, the Social Security Administration handles applications at SSA.gov.

The Gap Between Coverage on Paper and Coverage in Practice

Here is where it gets frustrating. I have read through the CMS guidance and the plan marketing materials, and there is a meaningful distance between “Medicare can cover GLP-1s” and “your specific plan covers your specific drug.”

As of the 2026 plan year, CMS data shows that roughly 60% of Medicare Advantage enrollees are in plans that offer some form of GLP-1 coverage for obesity. That sounds good until you realize it means 40% still have no coverage, and the 60% figure includes plans with very restrictive prior authorization requirements.

Standard Part D (non-Medicare Advantage) coverage for obesity-only GLP-1 indications remains limited. The cardiovascular indication for Wegovy gives the most reliable path to Part D coverage in standalone plans.

Zepbound (tirzepatide for obesity) does not have the same FDA-approved cardiovascular indication as Wegovy yet, though Lilly has a cardiovascular outcomes trial running. Plans that cover Zepbound for obesity are doing so under supplemental benefits or through broader formulary decisions, and that coverage is less consistent.

A Quick Comparison: Coverage Pathways by Drug

Note: Ozempic and Mounjaro are approved for Type 2 diabetes. Medicare Part D has always covered them for diabetic patients. If you have T2D and your doctor prescribes either of these, coverage is generally not an issue. The entire GLP-1 Medicare coverage debate is really about non-diabetic patients using these drugs for obesity.

I am on Mounjaro personally. Because I have a T2D diagnosis, my coverage situation is different from someone using tirzepatide purely for obesity. When I was looking into what Medicare beneficiaries with obesity but without diabetes face, the coverage picture is genuinely more complicated.

How to Find Out If Your Specific Plan Covers GLP-1s

Step one is the Medicare Plan Finder at medicare.gov. You can enter your current prescriptions and see what your specific plan will charge. This is the most reliable source because it pulls from actual formulary data.

Step two is calling your plan directly. Ask specifically: “Does your plan cover [drug name] for obesity under a supplemental benefit?” Get the answer in writing (email or a reference number for the call).

Step three is talking to your prescribing doctor. Prior authorization for GLP-1s under Medicare requires documentation. Your doctor needs to submit clinical notes showing your BMI, comorbidities, previous weight loss interventions, and the specific clinical indication. A prior auth submitted without thorough documentation will get denied.

If you are denied, you have appeal rights. The Medicare appeals process for Part D denials includes a redetermination request, an independent review entity review, and further escalation. About 40% of Part D prior auth denials that are appealed get overturned, so an initial denial is not the end of the road.

What Happens If You Do Not Qualify

If your plan does not cover GLP-1s for obesity, you have a few options that are worth knowing about.

Manufacturer savings programs: Novo Nordisk’s NovoCare program offers Wegovy at $299/month for the oral pill and $349/month for the injection for cash-pay patients (as of March 2026). Lilly’s LillyDirect program offers Zepbound at $349/month for the 2.5mg dose and $499/month for 5mg and above. These are available regardless of Medicare status, but there is an important catch: federal law prohibits Medicare beneficiaries from using manufacturer coupons for drugs covered under Medicare. If Medicare covers your GLP-1, you cannot stack a manufacturer coupon on top.

If Medicare does not cover your specific drug for your specific indication, the manufacturer programs may be usable. Confirm with your plan and the manufacturer before assuming either way.

Telehealth GLP-1 providers: Companies like Ro, Hims, MEDVi, and Found offer GLP-1 programs outside the Medicare/insurance system. These are cash-pay and often use compounded semaglutide or tirzepatide. For Medicare beneficiaries who cannot access brand-name drugs through their plan, this has become a real option. Prices typically run $150-$350/month for compounded versions. For a full price breakdown of every option, see our cheapest GLP-1 options guide. If you want to explore getting GLP-1 medications without insurance entirely, we cover that path in a separate guide.

Switching Medicare Advantage plans: The annual enrollment period runs October 15 through December 7. If your current plan does not cover GLP-1s, the 2027 plan year will offer another opportunity to switch to one that does. Check formularies during open enrollment, not after.

The Part D Out-of-Pocket Cap and How It Changes the Math

Before the Inflation Reduction Act’s Part D redesign, there was no cap on what Medicare beneficiaries paid out of pocket for drugs in a year. Someone on a GLP-1 at $500/month in cost-sharing would pay $6,000+ annually.

The new $2,000 annual out-of-pocket cap (which took full effect in 2025) changes this significantly. Even if your monthly GLP-1 copay is $200, once you hit $2,000 for the year you pay nothing for the rest of the plan year for any covered drugs.

For someone paying $200/month in cost-sharing, they would hit the $2,000 cap in 10 months and get two months essentially free. Annualized, that is $2,000 instead of what used to be uncapped spending. For LIS beneficiaries, the $50 cap means $600/year maximum on GLP-1s, which is genuinely affordable compared to the pre-2025 reality.

This cap is one of the most underreported parts of the Medicare coverage story for GLP-1s.

The Clinical Case for Why This Coverage Matters

I track my body composition with DEXA scans every 12 weeks. Since starting Mounjaro, my lean-to-fat ratio has improved, and I have been very deliberate about protein intake and strength training to minimize muscle loss. The SURMOUNT-1 trial (NEJM, July 2022) showed tirzepatide at 15mg produced mean weight loss of 22.5% over 72 weeks, with lean mass accounting for about 34% of total weight lost. That is better lean mass preservation than semaglutide’s STEP 1 data, where lean mass was 39-45% of total weight lost. For more on what DEXA scans actually show during GLP-1 treatment, see my 6-month DEXA results on Mounjaro.

The point is that these drugs produce substantial, meaningful outcomes. The SELECT trial demonstrated a 20% reduction in major cardiovascular events with Wegovy. For an elderly Medicare population that skews toward higher cardiovascular risk, the case for coverage is not just about weight. It is about keeping people out of hospitals.

The average Medicare beneficiary who needs a GLP-1 for obesity is not a cosmetic case. They are often managing hypertension, pre-diabetes, sleep apnea, and joint pain simultaneously. The cost of not treating obesity in this population shows up as hospitalizations, surgeries, and downstream chronic disease management. Coverage for GLP-1s is cheaper for the system long-term, which is part of why CMS moved in this direction.

Practical Steps to Get GLP-1 Coverage Through Medicare in 2026

1. Check your current plan’s formulary at medicare.gov or by calling your plan.
2. Confirm which drug is covered and under what indication (cardiovascular vs. obesity supplemental benefit).
3. Ask your doctor to document your clinical history thoroughly before submitting a prior authorization: BMI, cardiovascular risk factors, prior weight loss attempts, and the specific indication.
4. If denied, file a redetermination request within 60 days. Include supporting documentation from your doctor.
5. If you have Extra Help/LIS, confirm your $50 cost-sharing cap with your plan in writing.
6. If your plan does not cover GLP-1s for obesity, note the open enrollment period (October 15 through December 7) to switch to a plan that does for 2027.

If you want more detail on the prior authorization process and what documentation actually works, our insurance coverage guide covers it in depth, including denial appeal templates.

FAQ

Does Medicare cover Wegovy in 2026?

Yes, in many cases. Medicare Part D plans can cover Wegovy for cardiovascular risk reduction in patients with BMI 27+ and established cardiovascular disease. Medicare Advantage plans can also cover it as a supplemental obesity benefit. Coverage is not universal, it depends on your specific plan. Check your plan’s formulary at medicare.gov.

Does Medicare cover Zepbound for obesity?

Zepbound coverage under Medicare for obesity (not diabetes) depends entirely on whether your Medicare Advantage plan elected to include it as a supplemental benefit. Standard Part D coverage for Zepbound as an obesity drug is limited as of March 2026. If you have Type 2 diabetes, Mounjaro (the same drug under a different approval) is typically covered under Part D.

Who qualifies for the $50/month GLP-1 copay under Medicare?

The $50/month cap applies specifically to beneficiaries enrolled in the Extra Help (Low-Income Subsidy) program. You generally qualify if your income is below about 150% of the federal poverty level. Dual-eligible beneficiaries (both Medicare and Medicaid) automatically get Extra Help. For beneficiaries without LIS, cost-sharing varies by plan but is subject to the $2,000 annual out-of-pocket cap.

Can I use a manufacturer coupon for Wegovy or Zepbound if I am on Medicare?

Generally no. Federal law prohibits Medicare beneficiaries from using manufacturer coupons for drugs covered under Medicare. If Medicare does not cover your specific GLP-1 for your specific indication, you may be able to use programs like NovoCare or LillyDirect. Confirm with your plan before assuming either direction.

What if my Medicare plan denies prior authorization for a GLP-1?

File a redetermination request within 60 days of the denial. Ask your prescribing doctor to write a detailed letter of medical necessity that documents your BMI, all cardiovascular risk factors, prior weight loss attempts, and the specific clinical indication. Around 40% of Part D prior auth appeals succeed. If that fails, you can escalate to an independent review entity and further to an administrative law judge.

Bottom Line

GLP-1 Medicare coverage in 2026 is real but uneven. The $50/month figure applies specifically to Extra Help beneficiaries whose plans actually cover the drug, and that combination does not apply to everyone. The cardiovascular indication for Wegovy gives the most reliable path to Part D coverage. Zepbound coverage for obesity is more plan-dependent. If you have Type 2 diabetes, coverage for Mounjaro or Ozempic through Part D has always been the cleaner path.

The $2,000 annual out-of-pocket cap, which rarely gets mentioned in GLP-1 coverage discussions, may matter more to non-LIS beneficiaries than the $50 figure does.

Check your specific plan’s formulary, get prior authorization documentation right on the first try, and do not give up after an initial denial.

For help comparing providers if you need to go outside Medicare, see our GLP-1 provider directory.

Related

Guides:

• Cheapest GLP-1 Online · Insurance Coverage · Side Effects
• Mounjaro Dosage Guide · Oral vs Injectable · Exercise and Muscle
• GLP-1 Without Insurance · Fat Loss vs Weight Loss · Wegovy Pill vs Injection

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides